Lundbeck has posted a strong set of financials for the first quarter this morning with revenues being driven again by its antidepressant blockbuster Cipralex.

Operating profit came in at 1.25 billion Danish kroner, about $215.5 million, up 32% on the like, year-earlier period. Revenues reached 3.85 billion kroner, up 15% at constant exchange rates.

Lexapro (escitalopram), sold in the USA by licensee Forest Laboratories, had sales of 727 million kroner, up 9%, while turnover of Lundbeck's own Cipralex brand of the antidepressant advanced 5% to 1.45 billion kroner.

The Alzheimer's disease drug Ebixa (memantine) climbed 17% to 611 million kroner, while sales of Azilect (rasagiline), for Parkinson’s disease, leapt 46% to 240 million kroner. Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, which was launched in the USA in November 2008, had sales of 119 million kroner, while the recently-launched Sabril (vigabatrin) for the treatment of refractory complex partial seizures and the treatment of infantile spasms, contributed 34 million kroner.

Chief executive Ulf Wiinberg said the first quarter “has been very strong” He added that “all key products are delivering good results and Cipralex continues to show solid growth across Europe and in most of our international markets”.

Mr Wiinberg said that “we are off to a good start to deliver on our financial guidance," namely sales of 14.3-14.8 billion kroner and earnings before interest and taxes of 3-3.4 billion kroner in 2010.